Merck Biopharma Korea said that Daewoong would market Concor, its cardiovascular disease treatment, from next year.
|Merck Biopharma Korea's cardiovascular disease treatment Concor|
Under the accord, Daewoong will be responsible for marketing activities, such as promoting the product to medical workers and managing sales personnel, while Merck BioPharma Korea maintains the permit for the product.
Concor is a beta-blocker that shuts off β-adrenergic receptors with indications for the treatment of hypertension, angina and chronic heart failure with decreased left ventricular contraction. In Korea, Concor 5mg and 2.5mg tablets received approval in 2000 and 2001, while receiving insurance benefits in February 2017.
"Merck aims to become a global innovator by strengthening its specialty care pipeline in oncology, infertility, and neurology," Merck Biopharma Korea General Manager Javad Alam said. "In addition to focusing on these key areas, Merck will continue to contribute to the improvement of the lives of Korean patients by continuing to supply Concor through Daewoong."
Daewoong Pharmaceutical CEO Jeon Seng-ho also said, "We are very pleased to acquire the sales right for Concor, an excellent product of Merck BioPharma, in Korea."
Based on verification 4-step marketing strategy and superior sales force of Daewoong, the company will do its best to contribute to the treatment and improvement of quality of life for people with hypertension and angina pectoris, Jeon added.